Business Valuation

Initial Public Offering (IPO)

Financial Reporting

Corporate Transaction 

A growing attention to the Biotech sector has been shown in the accelerating investments by Venture Capital funds and IPOs, as well as the expectation of innovative therapies amidst Covid-19. This article, therefore, provides a guide on Biotech investment analysis with highlighting the “3H” characteristics of Biotech industry—High inputs in R&amp;D, High Rewards, and High Risks, and demonstrating related valuation approaches for quantitative analysis.
 
Click <a href="../../../../../uploads/Investing_in_Biotech_-_A_Guide_to_Risk-Return_Analysis_with_Valuation_Techniquesv2_d1bdf4f384.pdf" target="_blank" rel="noopener">here</a> to read the full article.
 
<a href="../../../../../uploads/Investing_in_Biotech_-_A_Guide_to_Risk-Return_Analysis_with_Valuation_Techniquesv2_d1bdf4f384.pdf" target="_blank" rel="noopener"><img src="../../../../../uploads/cover_51fccbbb2f.jpeg" width="600" /></a>

127134377_m

CFA, FCPA, FCPA (Aust.), MRICS, RICS Registered Valuer
Vincent is the Founder and Managing Partner of AVISTA Group, who leads the firm’s Valuation Advisory, Risk Management Advisory, ESG Advisory and Corporate Advisory services in Hong Kong and the PRC.
Vincent has over 20 years of experiences in valuation advisory, M&amp;A advisory, business consulting and corporate investment, advising clients in a range of industries, including TMT, financial services, pharmaceutical, energy and etc. Hence, leading the firm to make breakthroughs in these areas.
Before founding AVISTA, Vincent served as an Associate Director of PwC and was in charge of the valuation division in Beijing. He has advised numerous large M&amp;A deals in both China and overseas for multinational corporations and Chinese state-owned enterprises. He also has extensive experiences in providing valuation services for US and HK IPO listing.
Vincent is the Vice Chairman of Business Valuation Committee and the Executive Council Member of The Hong Kong Independent Non-Executive Director Association (HKiNEDA), Reviewer of HKICPA Best Corporate Governance and ESG Awards, Head Juror of Institute of ESG and Benchmark (iESGB) Achievement Awards, and the member of Financial Reporting Valuation Advisory Panel of HKICPA.

VINCENT PANG

Managing Partner

ACA, CFA, FCPA, LL.M, MRICS, RICS Registered Valuer
Ivan is mainly responsible for business valuation, intangible asset valuation and financial instruments valuation for financial reporting purpose and consulting &amp; advisory purpose.
Ivan has over 13 years’ experience in valuation sector. Prior to joining AVISTA, Ivan has worked with KPMG in Risk Advisory Service and Assurance Departments. Ivan has led several local and overseas valuation and advisory projects across different industries for transaction, IPO and financial reporting purposes.

IVAN LUI

Partner

Hailey is responsible for business valuation, intangible asset valuation and financial instrument valuation service for financial reporting and consulting purposes.
Hailey graduated from Shanghai Jiao Tong University Antai College and has 18 years’ experience in valuation service and M&amp;A financial advisory service in China. Before joining AVISTA, Hailey was a manager in PricewaterhouseCoopers with working experience in both Valuation Service and Corporate Finance Department.
During the past years, Hailey has participated in several large M&amp;A deals to provide modeling, pricing valuation or valuation advisory service. Besides, she was involved in numerous projects for US and HK listed or pre-IPO listing companies to review their valuation prepared for financial reporting purpose. In addition, she also acted as a financial advisor for several private equity financing and outbound acquisition projects.

HAILEY JIN

Investing in Biotech - A Guide to Risk-Return Analysis with Valuation Techniques

Taking reference to compliance development of other stock exchanges, previous consultations, and years of corporate governance reports review results, HKEX would like to introduce a series of listing rules amendments. A consultation paper has been published in June2024 to collect market’s feedback. According to the consultation paper, except for the proposed amendment in relation to long serving independent non-executive director(“INED”) and overboarding with a three-year transition period starting January 2028, other amendments will take effect since January 2025. Most amendments are newly introduced practices, and thus companies are recommended to arrange resources promptly to prepare for the new compliance requirements by 2025.
 
<a href="../../../../../uploads/Amendments_to_the_Hong_Kong_Stock_Exchange_s_Corporate_Governance_Code_and_Related_Listing_Rules_V6_e6b9c5f6f4.pdf" target="_blank" rel="noopener">Read the summary now</a>
<a href="../../../../../uploads/Amendments_to_the_Hong_Kong_Stock_Exchange_s_Corporate_Governance_Code_and_Related_Listing_Rules_V6_e6b9c5f6f4.pdf" target="_blank" rel="noopener"><img src="../../../../../uploads/Screenshot_2024_06_26_at_10_47_11_AM_313be3145b.png" width="500" /></a>

220976410_l_normal_none.jpg

Amendments to the Hong Kong Stock Exchange's Corporate Governance Code and Related Listing Rules

The International Accounting Standards Board (“IASB”) has published the Exposure Draft on Business Combinations — Disclosures, Goodwill and Impairment (the “Exposure Draft”) in March 2024, proposing changes to IFRS 3 and IAS 36 to improve the information provide to investors in order to help investors better assess management’s decision to make an acquisition and the performance of that acquisition. Companies should pay attention to the potential impact of the Exposure Draft and ensure their compliance with the latest rules and disclosure requirements.
 
<a href="../../../../../uploads/IASB_Exposure_Draft_on_Business_Combinations_Disclosures_Goodwill_and_Impairment_V3_79e696e4f5.pdf" target="_blank" rel="noopener">Read the report now</a>
<a href="../../../../../uploads/IASB_Exposure_Draft_on_Business_Combinations_Disclosures_Goodwill_and_Impairment_V3_79e696e4f5.pdf" target="_blank" rel="noopener"><img src="../../../../../uploads/Publication_Cover_EN_181fce7bbb.png" width="500" /></a>

Cover image.png

IASB Exposure Draft on  Business Combinations — Disclosures, Goodwill and Impairment

The Stock Exchange of Hong Kong Limited (the “HKEX”) has published the Guide for New Listing Applicants (the “Guide”), effective from 1 January 2024, introducing the new chapter on prospectus disclosure requirements and guidance in relation to Corporate Governance and Environmental, Social and Governance (“ESG”) (Chapter4.3 of the Guide). Listing applicants should pay attention to the impact of the Guide on the contents of the prospectus, in order to timely assess and optimize the proposed listing timetable.
 
<a href="../../../../../uploads/HKEX_s_Latest_Prospectus_Disclosure_Requirements_on_Corporate_Governance_and_Environmental_Social_and_Governance_under_the_Guide_for_New_Listing_Applicants_V6_5de8f68b61.pdf" target="_blank" rel="noopener">Read the report now</a>
<a href="../../../../../uploads/HKEX_s_Latest_Prospectus_Disclosure_Requirements_on_Corporate_Governance_and_Environmental_Social_and_Governance_under_the_Guide_for_New_Listing_Applicants_V6_5de8f68b61.pdf" target="_blank" rel="noopener"><img src="../../../../../uploads/Screenshot_2024_01_19_at_6_41_52_PM_e6c9255108.png" width="500" /></a>

Screenshot 2024-01-19 at 6.50.37 PM.png

HKEX’s Latest Prospectus Disclosure Requirements on Corporate Governance & Environmental, Social and Governance under the Guide for New Listing Applicants 